Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives Consensus Recommendation of “Buy” from Analysts

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned a consensus rating of “Buy” from the ten ratings firms that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $46.4286.

A number of research firms have issued reports on AAPG. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price objective on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th.

Ascentage Pharma Group International Stock Down 3.6%

Ascentage Pharma Group International stock opened at $17.42 on Friday. Ascentage Pharma Group International has a 52 week low of $16.36 and a 52 week high of $48.45. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. The business’s 50-day simple moving average is $18.39 and its 200-day simple moving average is $22.09.

Institutional Trading of Ascentage Pharma Group International

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the third quarter worth about $383,000. Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International in the 2nd quarter valued at $391,000. Finally, UBS Group AG raised its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.